These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24210066)

  • 1. Statins against drug-induced nephrotoxicity.
    Dashti-Khavidaki S; Moghaddas A; Heydari B; Khalili H; Lessan-Pezeshki M; Lessan-Pezeshki M
    J Pharm Pharm Sci; 2013; 16(4):588-608. PubMed ID: 24210066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity.
    Nasiri-Toosi Z; Dashti-Khavidaki S; Khalili H; Lessan-Pezeshki M
    Eur J Clin Pharmacol; 2013 May; 69(5):1057-73. PubMed ID: 23179178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature.
    Dashti-Khavidaki S; Shahbazi F; Khalili H; Lessan-Pezeshki M
    J Pharm Pharm Sci; 2012; 15(1):112-23. PubMed ID: 22365093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of short-term high-dose statins on the prevention of contrast-induced nephropathy in patients undertaking coronary angiography: a systematic review and meta-analysis].
    Zhou Y; Yuan WJ
    Zhonghua Nei Ke Za Zhi; 2011 Nov; 50(11):942-6. PubMed ID: 22333127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A Meta-analysis of Randomized Controlled Trials.
    Liu YH; Liu Y; Duan CY; Tan N; Chen JY; Zhou YL; Li LW; He PC
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):181-92. PubMed ID: 25193735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis.
    Zhang T; Shen LH; Hu LH; He B
    Am J Nephrol; 2011; 33(4):344-51. PubMed ID: 21430372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis.
    Zhou Y; Yuan WJ; Zhu N; Wang L
    Clin Nephrol; 2011 Dec; 76(6):475-83. PubMed ID: 22105451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Hydroxy-3-methylglutaryl-CoA reductase enzyme inhibitors for prevention of contrast-induced nephropathy: a meta-analysis of prospective randomized controlled studies.
    Briasoulis A; Mallikethi-Reddy S; Sharma S; Briasouli AA; Afonso L
    Am J Ther; 2015; 22(6):e158-66. PubMed ID: 25187093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins role in preventing contrast-induced acute kidney injury: a scoping review.
    Anjum I; Akmal M; Hasnain N; Jahangir M; Sohail W
    Hong Kong Med J; 2019 Jun; 25(3):216-221. PubMed ID: 31178439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and contrast-induced acute kidney injury with coronary angiography.
    Gandhi S; Mosleh W; Abdel-Qadir H; Farkouh ME
    Am J Med; 2014 Oct; 127(10):987-1000. PubMed ID: 24852935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of statins in preventing contrast-induced nephropathy: an updated meta-analysis.
    Xie H; Ye Y; Shan G; Zhang S; Fang Q; Yang D; Zeng Y
    Coron Artery Dis; 2014 Nov; 25(7):565-74. PubMed ID: 25036858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic considerations for the use of statin therapy in chronic renal disease.
    Moore R
    Nephron Clin Pract; 2003; 95(4):c107-15. PubMed ID: 14694271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of statin therapy on the progression of chronic kidney disease.
    Shah S; Paparello J; Danesh FR
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues.
    Campese VM; Ku E; Bigazzi R; Bianchi S
    J Nephrol; 2011; 24(5):550-3. PubMed ID: 21887675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin improves renal organic anion transporter 3 and renal function in gentamicin-induced nephrotoxicity in rats.
    Jaikumkao K; Pongchaidecha A; Chattipakorn N; Chatsudthipong V; Promsan S; Arjinajarn P; Lungkaphin A
    Exp Physiol; 2016 Jun; 101(6):743-53. PubMed ID: 27005971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin pleiotropy against renal injury.
    Kostapanos MS; Liberopoulos EN; Elisaf MS
    J Cardiometab Syndr; 2009; 4(1):E4-9. PubMed ID: 19245508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-induced nephropathy: do statins offer protection?
    Sadat U
    Curr Opin Cardiol; 2011 Jul; 26(4):334-7. PubMed ID: 21537166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.